🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against drug-resistant strains of the infection, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are escalating around the world, with estimates suggesting over 82 million instances annually. Notably increased rates are reported in Africa and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the context of rising global incidence, the spread of superbugs and the highly restricted therapeutic options presently on offer.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has listed it as a "priority pathogen". Ongoing monitoring found that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Receive Clearance

Zoliflodacin, alternatively called a brand name, was approved by the US FDA in mid-December for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers hope that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in close succession. This medication, which is additionally indicated for UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This approval represents a significant shift in the treatment of superbug gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Testing Data and Worldwide Availability

As per data published in a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This places it at an comparable level with the current standard treatment, which combines a dual-drug approach. The trial enrolled hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to make available and distribute the drug in a wide range of regions with limited resources.

Medical professionals treating patients have voiced hope. Access to a single-dose, oral treatment such as this is described as a "game-changer" for gonorrhoea control. This is deemed essential to lessen the impact of the disease for individuals and to halt the transmission of untreatable gonorrhoea globally.